MIH
VRTX icon

Meitav Investment House’s Vertex Pharmaceuticals VRTX Stock Holding History

Meitav Investment House’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-782
Closed -$269K – 547
2023
Q1 		$269K Hold
782
– – ﹤0.01% 328
2022
Q4 		$234K Hold
782
– – ﹤0.01% 340
2022
Q3 		$234K Hold
782
– – ﹤0.01% 338
2022
Q2 		$230K Buy
+782
New +$209K ﹤0.01% 319

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meitav Investment House's VRTX Position: Q2 2023 in Review

Meitav Investment House sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 782 shares — an estimated $269K sold.

Meitav Investment House first reported a position in VRTX in Q2 2022 and held it in 4 quarters. The position peaked at $269K in Q1 2023. 1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

  • Meitav Investment House reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Meitav Investment House sold 782 Vertex Pharmaceuticals shares in Q2 2023, an estimated $269K.
  • Meitav Investment House first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • Meitav Investment House's Vertex Pharmaceuticals position peaked at $269K in Q1 2023.
  • 1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Meitav Investment House's 13F filing for Q2 2023, filed 24 Jul 2023.